The use and tolerability of Crotalidae Polyvalent Immune FAB (Ovine) in pediatric envenomations

Henry C Farrar1, Taylor Grayham, Branson Bolden

  • 1University of Arkansas for Medical Sciences, Little Rock, AR, USA. farrarhank@uams.edu

Clinical Pediatrics
|April 19, 2012
PubMed

Insights

Crotalidae Polyvalent Immune FAB-Ovine (CroFab) is generally safe for children with snakebites. Adverse reactions were mild and did not prevent further use, indicating good tolerability in pediatric patients.

Area of Science:

  • Toxicology
  • Pediatric Medicine
  • Pharmacology

Background:

  • Limited data exist on Crotalidae Polyvalent Immune FAB-Ovine (CroFab) use in pediatric crotalid envenomations.
  • Assessing the safety and tolerability of CroFab in children is crucial for effective snakebite management.

Purpose of the Study:

  • To evaluate the safety and tolerability of CroFab in a pediatric population.
  • To analyze adverse drug reactions associated with CroFab administration in children.

Main Methods:

  • Retrospective chart review of pediatric patients admitted for snakebite over an 8-year period.
  • Analysis of data from 82 pediatric patients who received CroFab for crotalid envenomations.

Main Results:

  • Children receiving CroFab often had bites to extremities and more severe envenomations, indicated by longer hospital stays and increased need for surgery.
  • Adverse drug reactions occurred in 7.3% of pediatric patients, presenting as mild allergic symptoms.
  • Reactions were manageable with minimal intervention and did not preclude further CroFab use.

Conclusions:

  • Crotalidae Polyvalent Immune FAB-Ovine (CroFab) is typically well-tolerated in pediatric patients.
  • The safety profile of CroFab supports its use in managing crotalid envenomations in children.
  • Further research may explore optimal dosing and long-term outcomes in pediatric populations.

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...